Bortezomib
- Generic Name
- Bortezomib
- Brand Names
- Velcade, Bortezomib Accord, Bortezomib Hospira, Bortezomib Fresenius Kabi, Bortezomib Sun
- Drug Type
- Small Molecule
- Chemical Formula
- C19H25BN4O4
- CAS Number
- 179324-69-7
- Unique Ingredient Identifier
- 69G8BD63PP
- Background
Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest and apoptosis of cancer cells, is though...
- Indication
Bortezomib is indicated for the treatment of adults with multiple myeloma or mantle cell lymphoma.
- Associated Conditions
- Mantle Cell Lymphoma (MCL), Multiple Myeloma (MM)
- Associated Therapies
- -
Bortezomib-based Regimen for Refractory or Relapsed Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2023-09-13
- Last Posted Date
- 2024-04-18
- Lead Sponsor
- Instituto do Cancer do Estado de São Paulo
- Target Recruit Count
- 50
- Registration Number
- NCT06034561
- Locations
- 🇧🇷
Instituto do Cancer do Estado de Sao Paulo, São Paulo, SP, Brazil
Bortezomib in Patients with Metastatic Castration-Resistant Prostate Cancer with PTEN Deletion
- Conditions
- Interventions
- First Posted Date
- 2023-09-08
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- University of Utah
- Target Recruit Count
- 22
- Registration Number
- NCT06029998
- Locations
- 🇺🇸
Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States
Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis
- Conditions
- Interventions
- Procedure: Biospecimen CollectionProcedure: Autologous Hematopoietic Stem Cell TransplantationProcedure: BiopsyProcedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyDrug: BortezomibDrug: Daratumumab and Hyaluronidase-fihjProcedure: Computed TomographyDrug: MelphalanProcedure: Stem Cell IsolationDrug: CyclophosphamideDrug: DexamethasoneProcedure: EchocardiographyOther: Survey AdministrationProcedure: Magnetic Resonance ImagingProcedure: Positron Emission Tomography
- First Posted Date
- 2023-09-05
- Last Posted Date
- 2024-07-08
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 338
- Registration Number
- NCT06022939
- Locations
- 🇺🇸
Boston Medical Center, Boston, Massachusetts, United States
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸Siteman Cancer Center-South County, Saint Louis, Missouri, United States
Mitigate Immune-Mediated Loss of Therapeutic Response to Asfotase Alfa (STRENSIQ®) for Hypophosphatasia
- Conditions
- Interventions
- First Posted Date
- 2023-08-29
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT06015750
- Locations
- 🇬🇧
Research Site, Manchester, United Kingdom
Alvocade® (Bortezomib) Safety and Effectiveness Study
- First Posted Date
- 2023-08-25
- Last Posted Date
- 2023-08-25
- Lead Sponsor
- NanoAlvand
- Target Recruit Count
- 57
- Registration Number
- NCT06012383
SVRd for the Treatment of Newly Diagnosed Multiple Myeloma Patients Presenting With Extramedullary Disease
- Conditions
- Interventions
- First Posted Date
- 2023-06-13
- Last Posted Date
- 2023-08-14
- Target Recruit Count
- 35
- Registration Number
- NCT05900882
- Locations
- 🇨🇳
Nanjing First People's Hospital, Nanjing, Jiangsu, China
🇨🇳The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China
🇨🇳Taizhou People's Hospital, Taizhou, Jiangsu, China
High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Sitagliptin for the Prevention of GVHD
- First Posted Date
- 2023-06-08
- Last Posted Date
- 2024-04-29
- Lead Sponsor
- Indiana University
- Registration Number
- NCT05895201
- Locations
- 🇺🇸
Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana, United States
Teclistamab-Daratumumab and Talquestamab-Daratumumab in Newly Diagnosed High-risk Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2023-05-09
- Last Posted Date
- 2023-11-29
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 30
- Registration Number
- NCT05849610
- Locations
- 🇪🇸
Hospital Doce de Octubre, Madrid, Spain
🇪🇸Hospital Clinic i Provincial de Barcelona, Barcelona, Spain
🇪🇸Hospital Virgen de la Arrixaca, Murcia, Spain
TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II
- First Posted Date
- 2023-05-08
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Tanja Andrea Gruber
- Target Recruit Count
- 90
- Registration Number
- NCT05848687
- Locations
- 🇺🇸
Phoenix Children's Hospital, Phoenix, Arizona, United States
🇺🇸Arkansas Children's Hospital, Little Rock, Arkansas, United States
🇺🇸Children's Hospital Los Angeles, Los Angeles, California, United States
Bortezomib for the Treatment of Refractory Rheumatoid Arthritis
- First Posted Date
- 2023-04-10
- Last Posted Date
- 2023-08-30
- Lead Sponsor
- Chinese SLE Treatment And Research Group
- Target Recruit Count
- 20
- Registration Number
- NCT05805891
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.